ERBB2 and breast carcinoma: Neratinib (HKI-272) is a potent irreversible inhibitor of HER1, 2, and 4, which is highly active against HER2-overexpressing human breast cancer cell lines in vitro, with the potential to overcome resistance to trastuzumab in HER2-amplified breast cancer cells [49].